Find Clinical Trials for Uveal Melanoma

Every trial translated to plain English. Free. No login required.

83 trials

Testing a New Drug (Darovasertib) to Help Prevent Eye Cancer from Spreading

IDEAYA BiosciencesPHASE2Active

This trial is testing whether a new drug called darovasertib can help protect you from uveal melanoma coming back or spreading to other parts of your body. Here's how it works: you'll take this drug by mouth for up to 12 months *before* you have your main eye cancer treatment (either surgery to remove your eye or radiation therapy). The goal is to start fighting the cancer cells early, before your doctor removes the tumor or treats it with radiation. After your main treatment, you may continue taking the drug for another 6 months to keep working against any cancer cells that might be hiding. Doctors will then follow you for up to 3 years to watch for any signs that the cancer has come back or spread. This is a Phase 2 trial, which means the drug has already been tested in a small group of people and showed some promise—now doctors want to see if it really works and is safe in more patients like you. You'll be closely monitored throughout, with regular check-ups to make sure the drug is helping and not causing serious side effects. This trial offers a chance to try a new approach that might give you better odds of staying cancer-free.

NCT05907954
18 sites

Testing a New Targeted Drug (NN3201) for Eye Cancer and Other Tumors That Have a c-Kit Protein

Novelty Nobility, Inc.PHASE1Recruiting

This study is testing a new drug called NN3201 that is designed to find and attack cancer cells that have a specific protein called c-Kit on their surface. If you have uveal melanoma (eye cancer) or certain other cancers with c-Kit, this trial might be an option for you. The drug works like a guided missile: it's an antibody (your body's natural defense protein) that's been engineered to carry a toxic payload directly to cancer cells that display c-Kit, while trying to spare healthy cells. The study has two main parts. First, doctors will test different doses of NN3201 to figure out what dose is safe and what side effects to expect—this is called the "dose escalation" phase. Once they find the right dose, the second part will enroll more patients to confirm the drug works and continues to be safe. For uveal melanoma patients, you would be part of a group that includes other rare cancers with c-Kit. You'll receive the drug through an IV (intravenous) infusion, and doctors will closely monitor you with blood tests and check-ups to watch for any problems. Before joining, know that this is a Phase 1 trial, which means the drug is still being tested for safety—it's earlier stage research. You may experience side effects, and there's no guarantee the drug will shrink your tumor. However, if standard treatments haven't worked or aren't an option for you, this trial offers access to a completely new approach.

NCT06805825
5 sites

Testing Two Cancer-Fighting Drugs Together for Advanced Eye Melanoma

H. Lee Moffitt Cancer Center and Research InstitutePHASE2Recruiting

This trial tests whether combining two different drugs—olaparib and pembrolizumab—works better than either drug alone for advanced uveal melanoma (melanoma that started in your eye). Here's how it works: Pembrolizumab is an 'immune checkpoint inhibitor,' which means it's like removing the brakes on your immune system so your body's own cancer-fighting cells can attack the melanoma more effectively. Olaparib is a 'PARP inhibitor,' which works differently—it damages the cancer cells' ability to repair their own DNA, making them more vulnerable to dying. You would receive both drugs on a 3-week cycle: pembrolizumab as an infusion on day 1 of each cycle, and olaparib as pills you take by mouth for all 21 days. The idea is that these two drugs attack melanoma in different ways, and together they might be more powerful than either one alone. This is a Phase II trial, which means researchers have already seen some promise in earlier testing and now want to see if it really works and is safe in a larger group of patients like you.

NCT05524935
1 site

Testing a New Drug to Stop Uveal Melanoma from Coming Back

University of MiamiPHASE2Recruiting

This trial is testing whether a drug called quisinostat can help prevent your uveal melanoma from spreading or returning after surgery. You've already had your eye tumor removed, but doctors know that some patients with high-risk melanoma are more likely to develop cancer elsewhere in their body. This study wants to see if taking quisinostat regularly can reduce that risk. If you join, you'll take quisinostat as a capsule by mouth three times each week, following a schedule where you take it for a few days, then have a break. Each cycle lasts 21 days. Researchers will monitor you closely to see how the drug affects your body and whether it helps prevent the cancer from returning. This is a Phase 2 trial, which means the drug has already been tested for basic safety, and now doctors want to learn if it actually works for uveal melanoma patients.

NCT06932757
1 site

Testing a New Radioactive Drug to Treat Melanoma That Has Spread

Alpha-9 Oncology USA Inc.PHASE1Recruiting

This trial is testing a new investigational drug called A9-3408 to see if it can safely treat melanoma (including uveal melanoma, the eye cancer form) that has spread to other parts of your body or cannot be surgically removed. The drug works by using a radioactive particle attached to a targeting molecule—think of it like a guided missile that seeks out and destroys cancer cells while minimizing damage to healthy tissue. You would receive this drug as an IV infusion once every 6 weeks, for up to 6 treatments total (about 9 months). Before starting, you'll get a diagnostic scan using a different radioactive tracer to confirm the drug can find your cancer cells. Throughout the trial, you'll have regular doctor visits and tests to check how well the drug is working, monitor for side effects, and measure how much radiation your organs are receiving. This is an early-stage trial (Phase 1-1b), which means researchers are still figuring out the safest and most effective dose. The main goals are to understand what side effects occur, find the highest safe dose, and see if the drug can shrink your tumors—especially if your cancer has stopped responding to other immunotherapy treatments.

NCT07076550
4 sites

Understanding Your Experience and Quality of Life During Eye Cancer Monitoring

Institut CurieN/ANot Yet Recruiting

This study wants to understand what it's like for you to live with uveal melanoma after treatment—especially during the monitoring phase when you're getting regular check-ups to make sure the cancer hasn't come back. Researchers will ask you about your quality of life, your worries about recurrence, and how well your doctors are communicating with you about your risk and care plan. You'll fill out questionnaires at 6 months and 12 months after your treatment ends, and some patients will also be invited to do interviews where you can talk more deeply about your experience. The study compares patients at low risk of recurrence with those at high risk to see if the intensity of monitoring and the information you receive affects how you're doing emotionally and physically.

NCT06073548
0 sites

A New Treatment Using Your Own Immune Cells to Fight Advanced Melanoma and Other Cancers

Anusha KalbasiPHASE1Recruiting

This trial is testing a completely new way to fight your cancer by using your own immune cells as a weapon. Here's how it works: doctors will take T cells (special white blood cells that naturally fight disease) from your blood, send them to a lab, and genetically modify them to recognize and attack your cancer. Think of it like giving your immune cells a new set of instructions and a targeting system so they can find and destroy cancer cells that would normally hide from your body's defenses. The modified cells are then put back into your body through an IV. Before you receive these modified cells, you'll get two chemotherapy drugs (cyclophosphamide and fludarabine) to prepare your body—this is like clearing the battlefield so your new immune cells can work effectively. This is a Phase 1 trial, which means doctors are still figuring out the right dose and watching carefully for side effects. You'll have regular blood tests, scans (CT, PET, and MRI), and biopsies to see if the treatment is working and how your body is responding. If your cancer doesn't improve after the first treatment, you may be able to receive a second dose of the modified cells. This trial is for people with advanced melanoma (including uveal melanoma, the type affecting the eye) or other solid tumors that have spread. You'll be followed closely for at least 15 years after treatment to monitor your long-term health and how long the benefits last.

NCT04119024
3 sites

Testing a New Pill (Roginolisib) Against Standard Treatment for Advanced Eye Melanoma

iOncturaPHASE2Active

This study is testing whether a new oral medication called roginolisib works better than standard treatments for uveal melanoma that has spread or gotten worse. You would be randomly assigned to either take roginolisib as a pill, or receive whatever treatment your doctor thinks is best for you. The researchers want to find out two main things: Does roginolisib help people live longer? And how does it affect your quality of life compared to standard options? You can join this study if you have advanced or metastatic uveal melanoma that has progressed even after at least one prior immunotherapy treatment. The cancer must be measurable on imaging scans (CT or MRI). About 85 patients total will participate across multiple medical centers. This is an 'open-label' study, which means you and your doctor will know which treatment you're receiving. There's no placebo (fake treatment) involved—you'll either get the new drug or a standard treatment option.

NCT06717126
16 sites

Testing a New Immune-Boosting Drug (MBS8) for Advanced Cancers, Including Eye Melanoma

MonTa Biosciences ApSPHASE1Recruiting

This is an early-stage trial testing a brand-new drug called MBS8(1V270) to see if it's safe and if it can help fight advanced cancers. The drug works by waking up your immune system to recognize and attack cancer cells. Researchers will give you the drug through an IV (a tube in your vein) in cycles, starting with small doses and gradually increasing them to find the right amount that works best without causing too many side effects. If you have uveal melanoma (eye cancer) that has already been treated with other immune therapies, you may be eligible for the second part of this trial. In that part, you'd receive MBS8 alone. If you have cutaneous melanoma (skin cancer) that stopped responding to a drug called Keytruda, you might receive MBS8 combined with Keytruda instead. Throughout the trial, doctors will take blood samples and tumor biopsies, and use imaging scans (MRI or CT) to watch how your cancer responds.

NCT04855435
5 sites

A New Treatment Combining a Liver-Targeting Device With Immunotherapy for Uveal Melanoma That Has Spread to the Liver

Vastra Gotaland RegionPHASE3Recruiting

This trial is testing whether adding a special device called PHP (percutaneous hepatic perfusion) to standard immunotherapy works better than immunotherapy alone for uveal melanoma that has spread to your liver. Here's what that means: uveal melanoma is eye cancer, and unfortunately, it can spread to the liver in about half of patients. When it does, the cancer is usually very hard to treat, and survival is typically measured in months rather than years. The trial compares two approaches. One group gets the PHP device treatment (which delivers chemotherapy directly into the liver where the cancer is) plus two types of immunotherapy drugs (ipilimumab and nivolumab). The other group gets just the two immunotherapy drugs at different doses. Both groups continue treatment for up to a year. The goal is to see if adding the PHP device helps you live longer without the cancer getting worse. This is a Phase 3 trial, which means the treatment has already shown promise in earlier testing and is now being tested in a larger group of patients to confirm it works. You'll be randomly assigned to one of the two treatment groups. This trial is important because current treatments for liver metastases don't work well, and researchers are looking for better options.

NCT06519266
6 sites

Combining a Liver-Targeted Chemotherapy with Immunotherapy for Advanced Eye Cancer

Leiden University Medical CenterPHASE1 / PHASE2Active

This trial is testing a new combination approach for uveal melanoma (eye cancer) that has spread to other parts of your body, especially the liver. The treatment combines two strategies: (1) a chemotherapy drug called melphalan that is delivered directly to your liver through a special catheter procedure, which limits damage to the rest of your body, and (2) two immunotherapy drugs (ipilimumab and nivolumab) that work together to help your immune system recognize and fight cancer cells throughout your entire body, including in places the liver treatment can't reach. The idea behind combining these treatments is that the liver-directed chemotherapy can shrink tumors in your liver while the immunotherapy drugs wake up your immune system to attack cancer anywhere it's hiding—in your lungs, bones, or other organs. Previous studies showed that the liver treatment alone helped some patients, but cancer often came back in other parts of the body. The immunotherapy drugs have shown promise in other types of melanoma, and researchers believe combining them with the liver treatment might work better than either approach alone. You should know this is still being tested to figure out the right doses and to see how well it actually works. The trial will monitor you closely for side effects, which can include fatigue, skin reactions, and immune-related inflammation in various organs. This is an active area of research because uveal melanoma is difficult to treat, and doctors are looking for better options for patients like you.

NCT04283890
1 site

A New Immune Cell Treatment for Advanced Eye Cancer and Head/Neck Cancer

Erasmus Medical CenterPHASE1 / PHASE2Recruiting

This trial tests a brand-new way to fight your cancer using your own immune cells. Here's what happens: doctors take T cells (your body's natural cancer-fighting cells) from your blood and reprogram them in the lab to recognize and attack cancer cells that have a specific marker called MAGE-C2. This marker is found on many melanomas and head/neck cancers, but not on healthy cells—so the treatment is designed to target cancer while sparing your normal tissue. Before you receive the engineered cells back, you'll get a special drug (called an epigenetic drug) that makes cancer cells easier for your new T cells to spot and destroy. This is a first-of-its-kind trial, which means doctors are carefully watching to make sure the treatment is safe and actually works. You'll need to have a specific genetic marker called HLA-A*02:01 for this trial—think of it like a cellular barcode that determines whether your cells can work with this particular treatment. Unlike some other cancer treatments, you won't receive chemotherapy before getting your new T cells, which may mean fewer side effects. The whole process takes time: your cells are grown in the lab, and then you receive them back as an infusion.

NCT04729543
1 site

Understanding How Your Immune System Responds to a Targeted Liver Cancer Treatment

Massachusetts General HospitalNARecruiting

This study is for people with uveal melanoma (eye cancer) that has spread to the liver. Researchers want to understand how your body's immune system reacts to a specific treatment called Percutaneous Hepatic Perfusion (PHP) with melphalan—a chemotherapy drug delivered directly to your liver. Here's what happens: Before treatment, doctors will take a small tissue sample (biopsy) from your liver and draw blood to see what your immune system looks like at the start. Then you'll receive melphalan through PHP, which is a procedure that sends the chemotherapy directly into the blood vessels feeding your liver tumor, so the drug concentrates where it's needed most. About 3-4 weeks later, you'll come back for another liver biopsy and blood draw. By comparing your 'before' and 'after' samples, researchers can see how your immune cells changed and responded to the treatment. This research helps doctors understand whether PHP with melphalan not only shrinks tumors but also activates your immune system to fight the cancer. You're contributing to knowledge that could help future patients with the same diagnosis.

NCT07364474
1 site

Testing a New Cancer-Fighting Injection (ONM-501) Alone and With an Immune-Boosting Drug

OncoNano Medicine, Inc.PHASE1Recruiting

This trial is testing a new treatment called ONM-501 that is injected directly into your tumor. Researchers want to find the right dose that works best while being safe. The study has three parts: first, they'll test ONM-501 by itself; then they'll test it combined with cemiplimab (a drug that helps your immune system fight cancer); and finally, if they find doses that work, they'll expand the study to treat more patients with specific cancer types, including uveal melanoma. You would receive ONM-501 injections directly into your tumor once a week for three weeks, then have three weeks off before the cycle repeats. If you're in the combination group, you'd also receive cemiplimab through an IV every three weeks. This is a Phase 1 trial, which means it's early-stage research focused on safety and finding the right dose—not yet proven to cure cancer, but designed to learn if this approach is promising enough to study further.

NCT06022029
16 sites

Testing a New Cancer Drug (LNS8801) Alone and With Pembrolizumab for Advanced Cancers, Including Uveal Melanoma

Linnaeus Therapeutics, Inc.PHASE1 / PHASE2Recruiting

This study is testing a brand-new drug called LNS8801 to see if it can help fight advanced cancers, including uveal melanoma. The drug works by activating a specific protein in your body called GPER, which may help your immune system recognize and attack cancer cells. You'll take it as a pill three times a week or once or twice daily in 21-day cycles. The study has two main parts: first, doctors will test LNS8801 alone to find the right dose and make sure it's safe. Then, they'll test it combined with pembrolizumab (a drug that helps your immune system fight cancer). Up to 200 patients will participate at 15 hospitals across the United States. If you have uveal melanoma specifically, you'd be eligible if you've had 2 or fewer previous treatments and have no other standard treatment options left. Throughout the study, you'll have regular check-ups, blood tests, and imaging scans to monitor how the cancer responds and watch for any side effects.

NCT04130516
10 sites

A New Treatment for Early-Stage Eye Melanoma Using a Special Injection and Laser

Aura BiosciencesPHASE3Recruiting

This trial is testing a new treatment called belzupacap sarotalocan (bel-sar) for people with early-stage uveal melanoma or suspicious spots in the eye that might become cancer. The treatment works in two steps: first, doctors inject the medication into a specific space behind your eye using a tiny needle, and then they activate it with a special infrared laser. The goal is to destroy cancer cells while preserving your vision. You'll be randomly assigned to either receive the real treatment or a sham (fake) treatment—meaning you'll go through the same procedure, but some people won't receive the active drug or laser. Neither you nor your doctors will know which group you're in during the trial, which helps ensure fair results. This trial is testing whether bel-sar is safe and actually works better than doing nothing, so researchers can understand if this new approach is worth offering to patients like you.

NCT06007690
71 sites

A Two-Step Treatment for Large Eye Melanomas: Chemotherapy Followed by Radiation

Hospital das Clínicas de Ribeirão PretoPHASE1 / PHASE2Enrolling By Invitation

This trial tests a new way to treat large uveal melanomas (eye cancers) that are too big for standard radiation alone. Instead of removing your eye, doctors will try a two-step approach: first, they'll deliver chemotherapy (a cancer-fighting drug called melphalan) directly to the blood vessels feeding your tumor to shrink it, and then follow up with radiation therapy a few weeks later. Here's what happens: A doctor will thread a thin tube (catheter) through an artery in your groin up to the blood vessel that feeds your eye tumor, then inject the chemotherapy drug directly there. This targets the cancer while limiting damage to the rest of your eye. About 4 weeks later, you'll have radiation treatment using a small radioactive plaque (like a tiny seed patch) placed on your eye for a few days. Throughout the trial, you'll have regular eye exams, ultrasounds, and vision tests to see how well the treatment is working and to catch any side effects early. This is an early-stage trial (Phase 1/2), which means doctors are still learning the safest and most effective dose. You'd be helping them understand whether this approach can save eyes that might otherwise need to be removed.

NCT05893654
1 site

Testing a New Immune Treatment Combined With Liver-Focused Therapy for Eye Cancer That Has Spread

Thomas Jefferson UniversityPHASE1 / PHASE2Recruiting

This trial is testing whether combining a new drug called tebentafusp with treatments that target cancer in your liver can help people with uveal melanoma (eye cancer) that has spread to the liver. Tebentafusp works by training your immune system to recognize and attack cancer cells—think of it like giving your body's defense team a detailed photo of the enemy so they know what to look for. The trial has two main parts. Part 1 tests tebentafusp combined with a procedure called hepatic infusion (IE), where medicine is delivered directly into your liver's blood vessels to attack tumors there. Part 2 tests tebentafusp combined with TACE, a different liver procedure that cuts off blood supply to larger tumors and delivers chemotherapy directly to them. Both approaches aim to hit the cancer from two angles at once: your immune system attacking from within, and local treatments destroying tumors in your liver. Before you can join this trial, you'll need a blood test to check if you have a specific cellular marker called HLA-A*02:01—this is like a cellular barcode that determines whether your immune system can respond to this particular drug. If you qualify, you'll receive weekly infusions of tebentafusp, and depending on which part of the trial you're in, you'll also receive liver-directed treatments every 4 weeks. The doctors will monitor you closely with blood tests and imaging scans to see how well the treatment is working and to catch any side effects early.

NCT06626516
1 site

Understanding Iris Tumors Using Advanced Eye Imaging

Oregon Health and Science UniversityN/ARecruiting

This study is watching and learning—not treating. Researchers at Oregon Health and Science University want to understand iris tumors (tumors in the colored part of your eye) better by using a special camera called OCT angiography. This camera takes detailed pictures of blood vessels in your eye and can show whether a growth is a melanoma (dark tumor) or another type of iris lesion. You won't receive any new treatment in this study. Instead, doctors will compare images from healthy eyes to images from eyes with iris tumors to figure out what patterns help identify different types of tumors. This information could help doctors diagnose iris melanomas faster and more accurately in the future.

NCT03809585
1 site

Testing a New Drug Before Eye Cancer Surgery to Help Prevent the Cancer from Coming Back

IDEAYA BiosciencesPHASE3Recruiting

This study is testing whether giving you a new drug called darovasertib before your scheduled eye cancer treatment can help prevent your cancer from returning. Right now, doctors treat uveal melanoma (eye cancer) with either radiation seeds placed on your eye (plaque brachytherapy) or by removing the eye (enucleation). This trial asks: what if we give you darovasertib pills first to shrink or weaken the tumor, and then do the standard treatment? The hope is that this combination approach will work better than the standard treatment alone. You'll be randomly assigned to either receive darovasertib before your treatment (the new approach) or go straight to your standard treatment (the current approach). The drug is taken by mouth twice a day for cycles of 28 days. After your local therapy is complete, doctors will follow you for up to 3 years to check whether your cancer comes back, how well you can see, and how you're doing overall. This is a Phase 3 trial, which means the drug has already been tested in earlier studies and now researchers want to confirm it actually helps patients like you. You'll be cared for at multiple medical centers, and your doctors will know you're receiving the drug (it's not blinded).

NCT07015190
87 sites

Testing NBM-BMX, a New Drug That May Help Uveal Melanoma That Has Spread

Novelwise Pharmaceutical CorporationPHASE1 / PHASE2Recruiting

This study is testing a new drug called NBM-BMX to see if it can slow down or shrink uveal melanoma that has spread to other parts of your body. You'll take NBM-BMX as a capsule by mouth twice a day on an empty stomach. The drug works by targeting a specific problem in melanoma cells — it helps 'wake up' cancer cells that have gone into a dormant state, which may make your body's immune system better able to fight them. During the study, you'll visit the clinic about once every week or two for blood tests and scans to check how you're doing and whether the cancer is responding. Doctors will watch carefully for any side effects and adjust your dose if needed. You can keep taking the drug as long as it's helping and the side effects are manageable. This is an early-stage study (Phase 1b/2), which means doctors are still learning the best dose and how well it works, but it offers a chance to try a treatment specifically designed for your type of cancer. **Important:** You'll need to take this drug on a completely empty stomach — no food for 1 hour before or 2 hours after each dose, and no other medications within 1 hour before or 2 hours after. You also cannot take acid-reducing medications (like antacids or heartburn drugs) during the study, as they can prevent the drug from working properly.

NCT07136181
3 sites

Testing Two Drugs to Stop Eye Cancer from Spreading

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityPHASE2Active

This trial is testing whether two different medications—sunitinib or valproic acid, taken by mouth—can help prevent your uveal melanoma from spreading to other parts of your body after your eye surgery. You have high-risk melanoma, which means your cancer has a higher chance of coming back or spreading, so this preventive treatment (called "adjuvant therapy") is designed to catch any cancer cells that might be hiding before they cause problems. You'll be placed into one of three groups: Group 1 takes either sunitinib alone OR valproic acid alone for 6 months; Group 2 takes sunitinib alone for 12 months; or Group 3 takes both sunitinib and valproic acid together for 12 months. The doctors will watch you closely with check-ups every 3 months for the first 2 years, then every 6 months for 3 more years, and then once a year after that. The main goal is to see if these drugs help you stay cancer-free longer and live longer overall. This is a "randomized" trial, meaning a computer will randomly assign you to one of the treatment groups—you won't get to choose. The researchers are testing which approach works best because they don't yet know which one (or combination) is most effective for preventing uveal melanoma from spreading.

NCT02068586
1 site

Understanding How Uveal Melanoma and Its Treatment Affect Your Life

Leiden University Medical CenterN/ARecruiting

This study, called PROQEM, is designed to understand how an eye melanoma diagnosis and treatment affect your quality of life over five years. You're not receiving a new treatment in this study—instead, you're helping researchers learn about the real-world impact of the disease and standard treatments (like proton therapy or eye removal surgery) on patients like you. This information will help doctors better support future patients. If you join, you'll be asked to fill out questionnaires before your treatment and then at regular intervals (3, 6, 12, 24, 36, and 60 months after treatment). These questionnaires ask about how you're feeling emotionally, how well you're functioning in daily life, any eye symptoms you're experiencing, and how the diagnosis and treatment have affected your relationships and work. There's also a special sub-study (PROQEM-pco) for patients who have a choice between two different treatments—this part focuses on helping doctors understand how to better involve you in making that decision and whether you feel satisfied with your choice afterward. This is an observational study, meaning researchers are watching and documenting your experience rather than testing a new drug or procedure. Your honest feedback helps create a clearer picture of what patients actually go through, which can improve care for others in the future.

NCT05377957
1 site

Can a New Drug Called Tebentafusp Stop High-Risk Eye Cancer from Coming Back?

European Organisation for Research and Treatment of Cancer - EORTCPHASE3Recruiting

This study is testing whether a drug called tebentafusp can help prevent uveal melanoma from returning after you've had surgery or radiation to treat your eye cancer. Right now, doctors typically just watch and wait after treating high-risk eye melanoma—but about half of patients do experience their cancer coming back. Tebentafusp is a newer drug that has already been shown to help patients whose eye cancer has spread to other parts of the body. Researchers want to see if giving it to you earlier (right after your initial treatment, before any spread happens) might stop the cancer from returning in the first place. To join this study, you'll need to have a specific genetic marker called HLA-A*02:01—think of it like a cellular barcode that determines whether your immune system can recognize and fight this particular cancer. If you qualify and are randomly selected to receive the drug, you'll get weekly injections into your vein for about a year. The other group in the study will simply be monitored with regular check-ups. Researchers will then compare which group has fewer cancer recurrences over time.

NCT06246149
14 sites

A Study to Track Uveal Melanoma Over Time and Understand How It Develops

Columbia UniversityN/AActive

This is not a treatment trial—it's a tracking study. Researchers are building a national registry (a detailed database) to follow uveal melanoma patients over months and years to understand how the disease progresses, what happens after treatment, and when it might come back. Think of it like a long-term health journal that many hospitals will contribute to, so doctors can learn patterns they've never seen before. If you join, you'll be asked to share your medical information—your diagnosis, treatments you receive, imaging scans, and how you're doing over time. This information stays in the registry and helps researchers understand the natural history of uveal melanoma (how the disease naturally behaves without interference). Right now, there's no major study like this happening, so this data is really needed. You're not receiving a new drug or experimental treatment in this study. Instead, you'll continue your regular care with your eye cancer doctors and medical oncologists, and they'll report your progress to the registry. This helps future patients because doctors will have real-world information about what to expect and how to better manage the disease.

NCT04588662
17 sites

Testing a New Drug (Tebentafusp) for Melanoma Before It Comes Back

University of OxfordPHASE2Active

This study is testing whether a drug called tebentafusp can help prevent melanoma from coming back after surgery. Here's how it works: First, doctors will do a simple blood test to check if your cells have a specific marker called HLA-A*02:01 (think of it like a cellular barcode that determines if this drug can work for you). If you have this marker, you'll have blood tests every 3 months for up to 2 years to look for signs that cancer cells might be returning—even before you can feel or see anything wrong. This is called "molecular relapsed disease" or MRD. If doctors find these early warning signs, you'll be invited to receive tebentafusp treatment at a specialist center. If you're selected for treatment, you'll receive tebentafusp as an infusion (a needle in your vein) once a week for up to 6 months. The drug works by training your immune system to recognize and attack melanoma cells. After your treatment ends, doctors will continue monitoring you for another year to make sure the cancer doesn't come back. This study includes about 850 patients total—600 with skin melanoma and 250 with uveal (eye) melanoma like yours.

NCT05315258
10 sites

Testing a New Virus-Based Treatment Combined With Immunotherapy for Advanced Eye Melanoma

Replimune Inc.PHASE2 / PHASE3Recruiting

This trial is testing whether a new combination of two drugs works better than a standard combination for treating uveal melanoma that has spread to other parts of your body. You haven't received immune checkpoint inhibitor therapy before (this is a specific type of cancer treatment that helps your immune system fight cancer). One group will receive RP2 (a specially engineered virus designed to attack cancer cells and wake up your immune system) plus nivolumab (a drug that removes the 'brakes' on your immune cells). The other group will receive ipilimumab (a different immune-boosting drug) plus nivolumab. Researchers want to see which combination helps patients live longer and controls their cancer better, and which one has fewer side effects. You'll be randomly assigned to one of these two groups—like a coin flip—so neither you nor the doctors know in advance which treatment you'll receive.

NCT06581406
31 sites

Finding Hidden Genetic Causes of Eye Cancer That Run in Families

Centre Jean PerrinNARecruiting

This study is trying to solve a mystery: why does uveal melanoma (eye cancer) run in some families when doctors can't find the known genetic causes? Right now, doctors can only explain 1 in 5 cases of inherited eye cancer using the genes they know about. This research team thinks there are other genes they haven't discovered yet that make some families more likely to develop this cancer—and possibly other cancers like prostate, thyroid, or leukemia too. If you join this study, you'll help researchers find these hidden genes. Here's what happens: you'll meet with the research team to share your family's cancer history (they'll draw a family tree), and they'll collect a simple blood sample and a cheek swab. These samples will be analyzed to look for new genetic patterns. You won't get treatment from this study—it's purely research to help future families understand their risk and get better screening. This is detective work, not a treatment trial. But if researchers find new genes linked to eye cancer, it could help your family and others get earlier warning signs and more careful monitoring.

NCT06550674
1 site

A New Virus-Based Treatment That Fights Tumors and Boosts Your Immune System

Replimune Inc.PHASE1Active

This trial is testing a new treatment called RP2 that uses a specially modified virus to fight your cancer in two ways: it directly attacks tumor cells, and it wakes up your immune system to recognize and destroy cancer. The virus has been genetically engineered so it can only infect and kill cancer cells, not healthy ones. In the first part of the study, doctors will test different doses of RP2 alone to find the safest and most effective amount. In the second part, they'll combine RP2 with nivolumab (a drug that removes the 'brakes' your immune system puts on itself), which may make the treatment work even better. If you have uveal melanoma (eye cancer), lung cancer, breast cancer, or gastrointestinal cancer—especially if it has spread to your liver—you may be eligible for this trial. This is a Phase 1 trial, which means this is the first time this specific treatment is being tested in humans. Phase 1 trials focus on safety first—doctors want to make sure the treatment is tolerable and to find the right dose before testing whether it actually shrinks tumors. You'll be closely monitored throughout the study, and doctors will watch for any side effects. Because this is a new treatment, there are unknowns, but the goal is to develop a therapy that could help people with advanced cancers that are difficult to treat.

NCT04336241
6 sites

A New Way to Fight Cancer in the Brain and Spinal Cord Lining

M.D. Anderson Cancer CenterPHASE1Active

This trial is testing a new approach for patients whose cancer has spread to the lining around the brain and spinal cord—a serious condition called leptomeningeal disease. You'll receive a drug called nivolumab in two ways: a small injection directly into the fluid around your brain and spine, and an IV infusion into your bloodstream. The goal is to get your immune system to recognize and attack cancer cells in both places. This is a Phase I trial, which means doctors are still figuring out the safest dose and how well this combination works, so you'll be closely monitored with blood tests, spinal fluid samples, and imaging scans every few weeks. The treatment cycles happen every 2 weeks for the first 18 cycles, then every 4 weeks after that, as long as the cancer isn't getting worse and you're tolerating the treatment well.

NCT03025256
1 site

A Test to See If You Qualify for a New Personalized Cancer Treatment Study

TScan Therapeutics, Inc.N/AActive

This is a screening study—not a treatment study. TScan Therapeutics is developing a new type of cancer therapy that uses your own immune cells, specially trained to recognize and attack your specific cancer. But this therapy only works for certain patients, depending on your genetics and your tumor's characteristics. This screening study simply collects samples from you to run tests that will tell us if you're a good match for one of their treatment trials. You'll be asked to provide a cheek swab (like a Q-tip rubbed inside your mouth) and a saliva sample. These tests look at your HLA type—think of it as your immune system's genetic fingerprint. We'll also need a sample of your tumor tissue (either one you've already had removed and stored, or a fresh biopsy) to see if your cancer has the right 'markers' that the new therapy can target. No actual treatment happens in this screening study; it's just information gathering to see if you're eligible for the real treatment trial. If the tests show you're a match, you'll be invited to join one of TScan's actual treatment studies. If you're not a match, the screening results will still be valuable information for your doctors.

NCT05812027
21 sites

Can a Simple Blood Test Catch Eye Cancer Spread Early?

Hadassah Medical OrganizationN/ARecruiting

This study is looking for a way to catch uveal melanoma before it spreads to other parts of your body—or catch it very early if it does spread. Right now, doctors use imaging scans (like CT or MRI) to find metastases (cancer that has spread), but by the time those show up, the cancer may already be advanced. The researchers believe that cancer cells release tiny chemical signals into your bloodstream when they start to spread. If doctors can detect these signals with a simple blood test, they might catch metastases months or even years earlier than imaging can—when surgery to remove them could give you 10+ years of life instead of just 7-12 months. You'll have blood drawn regularly so researchers can measure these biomarkers over time. They're testing several different markers to see which ones are most reliable at predicting or detecting metastatic disease. This isn't a treatment—it's a diagnostic study to develop a better early warning system for you and other uveal melanoma patients.

NCT01438658
1 site

Training Your Own Immune Cells to Fight Metastatic Melanoma

Vastra Gotaland RegionPHASE1Not Yet Recruiting

This trial is testing a new way to fight melanoma that has spread to other parts of your body. Here's how it works: doctors will remove some of your own immune cells (called tumor infiltrating lymphocytes, or TILs) that are already fighting your cancer. They'll grow millions more of these cells in the lab, essentially creating an army of your body's own cancer-fighting soldiers. Then they'll put these cells back into your body—either directly into the liver through a special catheter, or through your bloodstream—along with two helper drugs (melphalan and interleukin-2) that boost their power. This is an early-stage trial (Phase 1), which means doctors are mainly checking if this approach is safe and if your body can handle it. You'll be closely monitored for side effects. The goal is to see if your own immune cells, when grown in large numbers and reinfused, can recognize and destroy cancer cells throughout your body. This trial is specifically for people with melanoma that has spread beyond the original tumor. If you're interested, your doctor will need to confirm you're a good candidate and that your cancer type matches what the trial is studying.

NCT07183852
0 sites

Can Melatonin Pills Help Prevent Eye Cancer from Spreading?

Gustav StalhammarPHASE3Recruiting

This study is testing whether taking melatonin pills every night for 5 years can help prevent uveal melanoma (eye cancer) from spreading to other parts of your body. Here's why this matters: about half of all people diagnosed with uveal melanoma will eventually develop cancer in other organs, usually the liver. Once that happens, treatment becomes very difficult and survival time is short. Researchers hope that melatonin—a natural substance your body already makes—might help keep any hidden cancer cells from waking up and growing. If you join this trial, you'll be randomly assigned to either take melatonin tablets (20 mg, taken at bedtime) or be in a control group that doesn't take the medication. Both groups will be followed closely for 5 years with regular liver scans every 6 months and blood tests. At the end, researchers will compare how many people in each group developed spreading cancer. This is a real test—nobody knows yet if melatonin will work, which is why the study is being done. This trial is run by St. Erik Eye Hospital in Sweden and is open to uveal melanoma patients across the country. It's not sponsored by a drug company, so the researchers are simply trying to find out if this affordable, natural approach might help.

NCT05502900
1 site

Combining Targeted Radiation and Immunotherapy for Metastatic Uveal Melanoma

California Pacific Medical Center Research InstitutePHASE2Recruiting

This trial tests a new combination approach for uveal melanoma that has spread to other parts of your body (usually the liver). You'll receive two treatments working together: focused radiation therapy that targets 1 to 5 specific tumors, and an immunotherapy drug called Opdualag that helps your immune system fight cancer cells throughout your body. The radiation is delivered in three quick doses over about a week, while the immunotherapy is given as an injection every 4 weeks for up to 2 years. The idea behind combining these treatments is that the radiation can help 'wake up' your immune system in the tumor area, making the immunotherapy work better. Right now, there's no standard treatment that works well for uveal melanoma that has spread, so this trial is exploring whether this combination might help more patients. Researchers will watch carefully for side effects and measure how well the tumors respond to treatment.

NCT05077280
1 site

A New Radioactive Treatment for Uveal Melanoma That Has Spread

Modulation Therapeutics, Inc.PHASE1Recruiting

This is an early-stage study testing a brand-new treatment called 225Ac-MTI-201 for uveal melanoma that has spread to other parts of your body. The treatment uses a radioactive particle attached to a targeting molecule—think of it like a tiny guided missile that finds and destroys cancer cells. You would receive one injection of this treatment, and the doctors will carefully watch how your body responds to figure out the right dose that works best while keeping side effects manageable. If you join this study, you'll be one of the first people to receive this treatment. That means doctors are still learning how it works and what side effects might happen. You'll need to stay overnight at the hospital after your injection and come back for regular check-ups—blood tests, scans, and physical exams—for at least the first month, then less frequently for up to 5 years. The goal is to see if this treatment can slow down or shrink your cancer while your body tolerates it well. This is a Phase 1 trial, which is the earliest stage of testing in humans. It's designed to find the safest and most effective dose, not to prove the treatment works yet. You should only consider this if other treatments haven't worked for you and you understand that this is experimental.

NCT05496686
1 site

Testing a New Immune-Boosting Cancer Drug (REGN10597) Alone or With Cemiplimab

Regeneron PharmaceuticalsPHASE1 / PHASE2Recruiting

This is an early-stage study testing a brand-new experimental drug called REGN10597 to see if it can help fight advanced cancers that have spread in the body. You may receive this drug by itself, or combined with another immune therapy drug called cemiplimab. The main goal is to figure out what dose is safe, what side effects happen, and whether the drug actually helps shrink tumors or slow cancer growth. This is a "first-in-human" study, which means REGN10597 has never been tested in patients before—only in the lab. The study has two phases: Phase 1 focuses on safety and finding the right dose (happening in the US), and Phase 2 expands to more patients worldwide to see if the drug actually works against cancer. Researchers will also check how long the drug stays in your blood and whether your immune system creates antibodies against it (which could affect how well it works). If you join, you'll have regular blood tests and imaging scans to monitor your health and how your cancer responds. This is a chance to access a cutting-edge treatment, but it also means accepting unknown risks since this drug is brand new in humans.

NCT06413680
11 sites

Tracking Eye Plaque Radiation Treatment for Eye Cancer: Finding the Right Dose

Duke UniversityN/AActive

This study is collecting information from patients like you who are receiving (or have received) eye plaque brachytherapy—a targeted radiation treatment for uveal melanoma. Doctors place a small radioactive plaque directly on your eye tumor, kind of like a tiny radiation patch that stays in place for several days. The research team will track your treatment details and long-term results to answer an important question: Can we use lower doses of radiation that still kill the cancer effectively, but cause fewer side effects like vision problems or damage to the eye? You're not receiving a new experimental drug or treatment—this study simply collects data from standard care to help future patients get the best possible outcomes.

NCT06432660
1 site

Understanding BAP1: A Gene That Increases Cancer Risk in Families

Mohamed Abdel-RahmanN/ARecruiting

This study is looking at a genetic change called a BAP1 mutation—think of it like an inherited instruction manual with a typo that makes your cells more likely to develop cancer. If you or your family members carry this mutation, you have a higher risk for several types of cancer, including uveal melanoma (eye cancer), skin cancer, kidney cancer, and others. This isn't a treatment trial; instead, researchers are trying to understand exactly how often these cancers develop in people with BAP1 mutations and what warning signs to watch for. Why does this matter for you? If you have uveal melanoma and might carry a BAP1 mutation, knowing this could change how doctors monitor you and your family members. For example, if researchers know you're at higher risk, your eye doctor can screen you more frequently to catch problems early—when treatment is most effective and vision can be saved. The same goes for your relatives: if they know they carry the mutation, they can get regular check-ups for skin, kidneys, and other organs before cancer develops. This study will help doctors create better screening plans and prevention strategies for people with BAP1 mutations and their families. **Important: You'll need genetic testing to find out if you have a BAP1 mutation before you can participate.**

NCT04792463
1 site

Testing One or Two Drugs to Stop Advanced Eye Cancer from Growing

National Cancer Institute (NCI)PHASE2Active

This trial is testing whether adding a second drug (GSK2141795) to a cancer medicine called trametinib makes it work better against uveal melanoma that has spread to other parts of your body. Both drugs work by blocking the 'growth signals' that tell cancer cells to multiply — think of it like cutting the power lines that fuel the cancer. You'll be randomly assigned to take either trametinib alone or trametinib plus GSK2141795, with pills taken by mouth once a day. The main goal is to see which approach keeps your cancer from growing longer. Researchers will also watch for side effects, measure how much the tumors shrink, and track how long patients survive. If your cancer starts growing again on trametinib alone, you may be able to switch to the combination treatment. You'll have check-ins every 4 weeks during treatment and then every 3 months after you finish.

NCT01979523
7 sites

Long-Term Follow-Up Study for Uveal Melanoma and Eye Lesion Patients

Aura BiosciencesN/ARecruiting

This study is following people like you who participated in a previous Aura Biosciences trial for uveal melanoma (eye cancer) or indeterminate lesions (spots in the eye that doctors are watching). The researchers want to understand how well the treatment worked over many years and whether any side effects develop later on. You're not receiving any new treatment in this study—instead, doctors will simply collect information from your regular eye care and cancer check-up appointments over at least 5 years. This helps Aura Biosciences and the medical community learn what happens to patients long-term, which can help future patients with the same condition.

NCT03941379
16 sites

Testing a Two-Drug Combination to Fight Uveal Melanoma That Has Spread

St Vincent's Hospital, SydneyPHASE1 / PHASE2Recruiting

This trial is testing whether combining two drugs—tebentafusp and IL-2—can work better together than tebentafusp alone to fight uveal melanoma that has spread to other parts of your body (usually the liver). Tebentafusp is a drug that teaches your immune system to recognize and attack cancer cells. IL-2 is a natural immune booster that helps your body fight cancer. Doctors want to see if adding IL-2 can help overcome cases where tebentafusp stops working and improve how long patients survive. If you join this trial, you'll receive both drugs on a repeating 28-day schedule. In the first cycle, you'll get IL-2 and tebentafusp on alternating days (starting with IL-2 on days 1-3, then tebentafusp on day 4, and so on). After that, the schedule becomes more regular, with both drugs given once a week. You'll have scans to check if your tumors are shrinking and blood tests to monitor how your body is responding. This is an early-stage trial, which means doctors are still learning the best dose and watching carefully for side effects. The goal is to find out if this combination can help you live longer and keep your cancer from growing. You'll need to have a specific genetic marker (HLA-A*02:01) to be eligible—your doctor can test for this.

NCT07063875
2 sites

A New Three-Drug Combination to Help Your Immune System Fight Melanoma

BioInvent International ABPHASE1 / PHASE2Active

This trial tests a new treatment approach for melanoma that has spread or cannot be surgically removed. You would receive three drugs together: two that doctors already use for melanoma (pembrolizumab and ipilimumab) plus a new drug called BI-1607. Think of it this way: pembrolizumab and ipilimumab are like removing the 'brakes' on your immune system so it can attack cancer cells. BI-1607 is designed to act like a 'turbocharger' for these two drugs, making them work even better together. The goal is to help your body's defense system destroy cancer cells more effectively than these drugs do alone. The trial has two parts. In Part 1, researchers will test different doses of BI-1607 and ipilimumab (starting with smaller amounts and increasing them) to find the safest and most effective combination. In Part 2, about 20 more patients will receive the dose that worked best from Part 1. You would receive these drugs through an IV (a tube into your vein) every three weeks for the first 12 weeks, then continue with pembrolizumab alone for up to 2 years total. Throughout the trial, doctors will monitor your health closely with blood tests, scans, and check-ins to watch for side effects and see if your tumors shrink. There's no guarantee this treatment will help you personally, but your participation could help future melanoma patients. The main risk is that these are powerful immune-boosting drugs, and they can cause serious side effects. Doctors will stop your treatment if side effects become too severe.

NCT06784648
9 sites

Testing a Two-Drug Combination (Pembrolizumab + Lenvatinib) for Metastatic Uveal Melanoma

Institut CuriePHASE2Active

This trial is testing whether combining two drugs—pembrolizumab and lenvatinib—works better together to fight uveal melanoma that has spread to other parts of your body. Pembrolizumab is an immunotherapy drug that helps your immune system recognize and attack cancer cells. Lenvatinib is a targeted therapy that slows cancer growth and improves blood flow to tumors, which may help your immune system work better. The researchers believe that together, these two drugs might be more powerful than either one alone. The trial is split into two groups based on whether you've previously received a treatment called Tebentafusp. This matters because the doctors think the combination might work differently depending on your treatment history. You'll receive pembrolizumab (up to 35 doses) and lenvatinib until your cancer stops responding or you experience unacceptable side effects. Every 9 weeks, you'll have imaging scans (MRI of your liver and CT of your chest, abdomen, and pelvis) to check how the cancer is responding. This is a Phase II trial, which means the drugs have already been tested for safety in earlier studies, and now researchers want to see how well this specific combination works for your type of cancer. You'll be followed closely throughout the trial and even after you stop treatment to monitor your health and survival.

NCT05282901
1 site

Testing a New Drug (DYP688) for Uveal Melanoma That Has Spread

Novartis PharmaceuticalsPHASE1 / PHASE2Active

This trial is testing a brand-new drug called DYP688 to see if it can help people with uveal melanoma (eye cancer) that has spread to other parts of the body. The drug is designed to target a specific genetic mutation called GNAQ or GNA11 — think of these as instructions in your cancer cells that tell them to grow. If your cancer has one of these mutations, this drug might be able to stop those instructions. The trial has two main parts. First, doctors will test different doses of DYP688 to find the safest and most effective amount (this is called the "dose escalation" phase). Once they figure out the right dose, the second part will test whether the drug actually shrinks tumors in different groups of patients — including people who have already tried another treatment called tebentafusp and people who haven't. You'll need a biomarker test to confirm your cancer has a GNAQ or GNA11 mutation before you can join. This is a "first in human" study, which means this is the first time DYP688 is being tested in people. Doctors will watch you closely for side effects and measure whether your tumors are getting smaller. Being part of this trial means you're helping doctors learn whether this new approach works.

NCT05415072
11 sites

Testing IDE196 to Target the Genetic Mutations That Drive Uveal Melanoma

IDEAYA BiosciencesPHASE1 / PHASE2Recruiting

This trial is testing a new drug called IDE196 that targets a specific genetic flaw found in many uveal melanomas. Your cancer cells likely have mutations in genes called GNAQ or GNA11—think of these as broken instructions that tell your cancer cells to grow. IDE196 is designed to block the faulty signal these mutations create, which may slow or stop your cancer from growing. The trial has two main phases. In Phase 1, doctors test different doses of IDE196 alone, or combined with other drugs (binimetinib or crizotinib), to find the safest and most effective dose. In Phase 2, they give more patients the best dose found in Phase 1 to see how well it actually works against the cancer. You'll take the drug by mouth twice a day in 28-day cycles. The trial is currently enrolling patients for Phase 2, and some parts are already full. Before you can join, you'll need a genetic test to confirm your tumor has one of these specific mutations. This test is essential because the drug only works if your cancer has this particular flaw.

NCT03947385
15 sites

Testing APG-115 Alone or With Pembrolizumab for Advanced Melanoma and Other Cancers

Ascentage Pharma Group Inc.PHASE1 / PHASE2Active

This trial is testing a new drug called APG-115, either by itself or combined with pembrolizumab (a well-known immunotherapy drug). The goal is to see if APG-115 can help your body's immune system fight cancer more effectively. Here's how it works: Cancer cells have a trick—they produce something called MDM2 that shuts down a protective protein in your body called p53 (think of p53 as your body's natural "cancer fighter"). APG-115 blocks MDM2, which wakes up p53 again. When combined with pembrolizumab (which removes the brakes on your immune system), the two drugs work together to help your immune cells recognize and destroy cancer cells. The trial has two phases: Phase 1b tests different doses of APG-115 combined with pembrolizumab to find the safest dose. Phase 2 uses that safe dose and tests whether APG-115 alone or combined with pembrolizumab actually shrinks tumors. You'll take APG-115 as a pill every other day for 2 weeks, then have a week off. Pembrolizumab is given as an IV infusion every 3 weeks. The trial includes about 230 patients with various advanced cancers, including uveal melanoma (eye cancer).

NCT03611868
21 sites

A Trial of Personalized Cancer-Fighting Cells for Advanced Solid Tumors

Immatics US, Inc.PHASE1 / PHASE2Recruiting

This trial tests a new treatment called IMA203 or IMA203CD8 that uses your own immune cells to fight cancer. Here's how it works: doctors will take some of your white blood cells, send them to a lab where scientists genetically modify them to recognize and attack cancer cells, and then put those enhanced cells back into your body. The goal is to see if this treatment is safe and if it can help people whose cancers have come back or stopped responding to other treatments. Some patients will also receive a drug called nivolumab, which helps your immune system work better. Before you start treatment, you'll need a biopsy (a small tissue sample from your tumor) to check if your cancer has a specific marker called PRAME—think of this like checking if your cancer has the right 'address' for this treatment to find it. You'll also need a blood test to check your HLA type, which is like a cellular barcode that determines if this treatment will work for you. If you're eligible, doctors will collect your white blood cells through a process called leukapheresis (similar to donating blood, but the machine separates out the white cells and returns the rest). Then comes the treatment phase: you'll receive chemotherapy drugs (cyclophosphamide and fludarabine) to prepare your body, followed by an infusion of your modified cells in the hospital. You may also get a low dose of IL-2, a protein that helps your immune cells survive longer. After that, you'll be closely monitored for 5 years.

NCT03686124
18 sites

Testing a New Immune-Boosting Drug (IOV-3001) Combined With Cell Therapy for Advanced Melanoma

Iovance Biotherapeutics, Inc.PHASE1 / PHASE2Recruiting

This is an early-stage study testing a brand-new drug called IOV-3001 in people with advanced melanoma (including eye melanoma) that has spread or can't be surgically removed. The drug is designed to work alongside lifileucel, which is a type of cell therapy that uses your own immune cells to fight cancer. Here's what happens: Doctors will give you IOV-3001 as a single infusion (injection into your vein) in a hospital. The drug is a fusion protein—think of it as two tools stuck together. One part is an antibody (your immune system's natural fighter), and the other part is a modified form of interleukin-2, a substance that supercharges your immune cells to attack cancer more aggressively. Depending on which part of the study you're in, you'll receive IOV-3001 either before or after your lifileucel treatment. Because this is the first time IOV-3001 is being tested in humans, the main goal is to make sure it's safe and to figure out the right dose. Researchers will carefully watch for side effects and measure whether the combination helps shrink tumors. This is early research, so there are unknowns—but if it works, it could offer a new option for people with advanced melanoma.

NCT06940739
4 sites

Combining Three Cancer-Fighting Treatments for Melanoma That Has Spread to the Brain

Emory UniversityPHASE1Active

This trial tests whether combining three different treatments works better than using just two for melanoma that has spread to your brain. The three treatments are: (1) immunotherapy drugs that wake up your immune system to fight cancer, (2) stereotactic radiosurgery, which is a focused beam of radiation that targets tumors in the brain very precisely, and (3) a wearable device called NovoTTF-200M that sends gentle electric pulses through patches on your skin to disrupt cancer cells' ability to divide and grow. You would be in one of two groups. Both groups get stereotactic radiosurgery and wear the NovoTTF device for 8 hours daily. Group 1 receives the immunotherapy drug pembrolizumab, while Group 2 receives two immunotherapy drugs (nivolumab and ipilimumab). The main goal right now is to make sure this combination is safe and to understand what side effects might happen. Researchers will also track whether the cancer shrinks, whether new tumors appear in your brain, and how long you survive. This is an early-stage trial (Phase 1), which means doctors are still learning the best way to use these treatments together. You'll be closely monitored during treatment and for 28 days after.

NCT05341349
1 site

Testing Tebentafusp Before Surgery for Uveal Melanoma That Has Spread to the Liver

Grupo Español Multidisciplinar de MelanomaPHASE2Recruiting

This trial is testing whether a drug called tebentafusp can shrink uveal melanoma tumors in your liver before surgery. Here's how it works: you'll receive tebentafusp as an IV infusion (through your vein) once a week for 6 months. During this time, doctors will scan your liver every 2 months to see how the tumors are responding. The goal is to shrink the tumors as much as possible—ideally to the point where no cancer cells remain (called a complete response). After 6 months, if the tumors have shrunk enough, you'll have surgery to remove them from your liver. After surgery, you'll continue taking tebentafusp for at least another year to help prevent the cancer from coming back. This trial is specifically for people whose uveal melanoma has spread only to the liver (not to other parts of the body) and whose tumors can potentially be removed with surgery. You'll need a special blood test first to make sure you have a specific genetic marker called HLA-A*02:01—tebentafusp only works for people who have this marker. The trial will enroll 19 patients total and closely monitor you with regular scans and blood tests to make sure the treatment is working and to catch any side effects early.

NCT07057596
4 sites

Testing a Two-Drug Combination to Treat Uveal Melanoma That Has Spread

Providence Health & ServicesPHASE2Active

This trial is testing whether two drugs working together—lenvatinib and pembrolizumab—can help treat uveal melanoma (eye cancer) that has spread to other parts of your body. You're eligible if you haven't received immunotherapy drugs before for this cancer. Here's how it works: you'll take lenvatinib as a daily pill (20 mg) and receive pembrolizumab as an IV infusion (a needle in your vein) every 3 weeks. The two drugs work differently—lenvatinib slows down cancer cell growth by blocking certain proteins, while pembrolizumab helps your immune system recognize and attack cancer cells. Together, researchers hope they'll be more effective than either drug alone. You would continue this treatment for up to 2 years, with regular check-ins to see how you're responding. This is a Phase II trial, which means the drugs have already been tested for safety in earlier studies, and now researchers want to see how well this specific combination actually works for uveal melanoma. The trial is being run at a single hospital location, so you'd receive all your care in one place.

NCT05308901
1 site

Can Exercise During Eye Cancer Treatment Help You Stay Healthier?

University of ValenciaNARecruiting

This study is testing whether doing resistance exercises (like using stretchy bands to build strength) during your hospital stay for eye cancer treatment can help your body stay healthier. You'll be in the hospital for 5-7 days while you receive plaque brachytherapy (a type of radiation treatment for uveal melanoma). During that time, you'll be isolated in your room, but instead of just resting, half of the patients in this study will do about 30 minutes of guided exercise each day using elastic resistance bands, while the other half will follow the hospital's normal routine. The researchers want to see if this exercise helps improve your blood health markers, physical strength, mood, and overall quality of life—both right after treatment and one month later. A trained doctor will supervise all the exercises and adjust the difficulty based on how hard you're working. The goal is simple: to find out if staying active during a tough week of treatment can actually help your body recover better.

NCT06970236
1 site

A New Two-Drug Combination (IDE196 + Crizotinib) for Metastatic Uveal Melanoma

IDEAYA BiosciencesPHASE2 / PHASE3Active

This trial is testing whether two drugs taken together—IDE196 and crizotinib—work better than standard treatments for uveal melanoma that has spread to other parts of your body. Both drugs are pills you take by mouth twice a day. The study will compare your results on this new combination against patients who receive one of three standard treatments (pembrolizumab, a combination of ipilimumab and nivolumab, or dacarbazine). The trial has three stages. First, doctors will test two different doses of IDE196 combined with crizotinib to find the best dose that works well and is safe. Once they pick the winning dose, more patients will be enrolled to confirm it works. Finally, the largest stage will compare this combination head-to-head with standard treatments, measuring how long patients survive. The main goal is to see if this new combination helps people with metastatic uveal melanoma live longer. **Important: You can only join this trial if you have a specific genetic marker called HLA-A*02:01 negative.** This means you'll need a blood test to check if you qualify before enrolling. This genetic difference affects how your immune system responds to these drugs.

NCT05987332
68 sites

A New Immune Cell Treatment for GD2-Positive Cancers That Have Come Back or Stopped Responding to Treatment

Baylor College of MedicinePHASE1Active

This trial is testing a new way to fight your cancer using your own immune cells. Doctors will take some of your blood and grow special white blood cells called T cells in the lab. They'll add two new genes to these cells: one that teaches them to recognize and kill cancer cells that have a marker called GD2 on them, and another that helps these cells survive longer in your body. Then they'll put these upgraded cells back into your blood. You might also receive chemotherapy drugs (cyclophosphamide and fludarabine) before getting the T cells. These drugs help make room in your body for the new T cells to work better. The T cells are given through an IV, and you'll stay in Houston for up to 4 weeks so doctors can watch for side effects. You might get a second dose of cells later if your cancer doesn't get worse and you don't have serious side effects from the first dose. This is an early-stage trial (Phase 1), which means doctors are still figuring out the right dose and how safe this treatment is. You'll have many follow-up visits and blood tests over 15 years to make sure the treatment is working and to watch for any long-term effects. This treatment is not yet approved by the FDA.

NCT03635632
2 sites

Testing Two New Immunotherapy Drugs for Cancers with a Specific Immune Marker

SOLTI Breast Cancer Research GroupPHASE2Active

This trial is testing whether two immunotherapy drugs—spartalizumab and tislelizumab—work better in patients whose tumors have high levels of a specific immune marker called PD1. Think of PD1 like a 'brake' on your immune system that cancer cells use to hide. These drugs are designed to release that brake so your own immune cells can recognize and fight the cancer. You would first have a small tumor sample tested to measure your PD1 levels. If your tumor has high PD1, you'd receive one of these drugs as an infusion (through an IV) once a month. The trial includes many cancer types, including uveal melanoma (eye cancer). This is a phase II trial, which means researchers are checking whether the drug actually works and is safe enough to study further—it's not yet proven to be better than standard treatments. You should know: this trial requires a specific biomarker test (PD1 mRNA expression) before you can join. The drugs work by boosting your immune system, which can sometimes cause side effects as your body fights back. Talk with your doctor about whether this trial makes sense for your specific situation.

NCT04802876
1 site

A New Treatment Using Your Own Immune Cells to Fight Advanced Uveal Melanoma

Memorial Sloan Kettering Cancer CenterPHASE1Recruiting

This trial tests a treatment called lifileucel that uses your body's own immune cells to fight uveal melanoma that has spread. Here's how it works: doctors remove immune cells called TILs (tumor infiltrating lymphocytes) from your tumor—these are cells your body already sent to fight the cancer. The cells are then grown in a lab for about 3 weeks to create millions of copies of your cancer-fighting cells. Then you receive chemotherapy to prepare your body, followed by an infusion of these boosted immune cells back into your bloodstream, plus a short course of a drug called IL-2 that helps these cells work harder. This is an early-stage trial (Phase 1), which means researchers are still learning how well this works and what side effects to expect. You would be one of the first patients to receive this specific treatment. The goal is to give your immune system a powerful, personalized weapon against your cancer—using cells that already know how to recognize and attack your tumor.

NCT05607095
2 sites

A New Treatment Using Your Own Immune Cells to Fight Melanoma That Has Spread to the Brain

Memorial Sloan Kettering Cancer CenterPHASE1Active

This trial tests a treatment called lifileucel (LN-144) for people with uveal melanoma that has spread to the brain and stopped responding to standard immunotherapy drugs (PD-1 inhibitors). Here's how it works: doctors remove a small piece of your tumor, then send it to a lab where they grow special immune cells called TILs (tumor-infiltrating lymphocytes) — these are your own white blood cells that were already fighting your cancer. Over about 3 weeks, the lab multiplies these cells so there are billions of them. Then they put them back into your body through an IV infusion. You'll also receive a mild chemotherapy preparation beforehand and a short course of a drug called IL-2 afterward to help these cells work better. This is an early-stage trial (Phase 1), which means doctors are still learning if this approach is safe and effective for brain metastases. You'll need to stay in the hospital for several weeks during treatment. This trial is for people whose cancer has spread to the brain but isn't causing symptoms yet, and whose previous immunotherapy treatments stopped working.

NCT05640193
1 site

Testing Vorinostat to Treat Eye Melanoma That Has Spread

National Cancer Institute (NCI)PHASE2Active

This trial is testing a drug called vorinostat to see if it can help people with uveal melanoma (eye cancer) that has spread to other parts of the body. Vorinostat works by blocking certain proteins that cancer cells need to grow and divide. You would take this drug by mouth twice a day, three days a week, in four-week cycles. The main goal is to find out how many people's tumors shrink or stop growing with this treatment. The researchers will also track how long you survive and how long your cancer stays stable without getting worse. They'll watch carefully for any side effects you experience. Additionally, they'll do blood tests and analyze tumor samples to understand why the drug works better for some people than others—this helps them learn which patients are most likely to benefit. After you finish taking the drug, you'll have follow-up visits every three months so the doctors can monitor your health.

NCT01587352
3 sites

A Study Looking Back at Uveal Melanoma Patients to Learn What Works Best

Medical University of ViennaN/ARecruiting

This is not a trial where you receive a new treatment. Instead, researchers at the Medical University of Vienna are creating a detailed record of patients with uveal melanoma who were treated there between 1997 and 2021. They're reviewing old medical charts and collecting information about what treatments patients received, how long they survived, and how their disease progressed over time. Why does this matter? Uveal melanoma is rare, which makes it hard for doctors to study. By carefully analyzing the medical records of many patients treated over 25 years, researchers can spot patterns about which treatments worked better, which patients did better or worse, and what factors matter most. This information helps doctors make better decisions for future patients like you. If you're eligible, your participation means allowing researchers to review your medical records and add your information (kept completely private) to their database. There are no new treatments to try, no extra appointments, and no additional procedures. You're simply helping doctors learn from your care to help others in the future.

NCT05733728
1 site

A Targeted Chemotherapy Treatment for Uveal Melanoma That Has Spread to the Liver

Thomas Jefferson UniversityPHASE2Active

This trial tests a specialized procedure called chemoembolization to treat uveal melanoma (eye cancer) that has spread to your liver. Instead of chemotherapy drugs traveling through your whole body, doctors inject them directly into the blood vessels feeding the tumors in your liver. This approach delivers a high dose of cancer-fighting medication right where it's needed while limiting side effects to the rest of your body. Here's how it works: A doctor guides a thin catheter (tube) into the artery that supplies blood to your liver tumors. They then inject a chemotherapy drug called carmustine mixed with a special oil, followed by tiny gelatin sponges that block blood flow to the tumors. This starves the cancer cells of oxygen and nutrients while exposing them to high doses of chemotherapy. You'll receive this treatment every 4 weeks (if cancer is in both sides of your liver) or every 7 weeks (if it's on one side), as long as the treatment is working and you're tolerating it well. You'll be closely monitored with scans and blood tests to see how your tumors respond. The main goal is to shrink or stop the growth of liver tumors and help you live longer. This is a Phase II trial, meaning researchers have already tested this approach in a smaller group and now want to confirm it works and understand its side effects better.

NCT04728633
1 site

Testing a New Immune-Boosting Drug Before Surgery or Radiation for Eye Cancer

Thomas Jefferson UniversityPHASE2Recruiting

This trial tests whether a drug called tebentafusp can shrink your eye cancer before you have surgery or radiation. Here's how it works: tebentafusp acts like a bridge between your cancer cells and your immune system's T-cells (your body's natural cancer fighters). By connecting these two, the drug tells your immune system to attack and kill the melanoma cells. You'll receive tebentafusp through an IV (a needle in your arm) four times over one month, and you can repeat this for up to two months if it's working well. Then, within four weeks of your last dose, you'll have your standard treatment—either radiation therapy or surgery to remove the eye, depending on what your doctor recommends. The main goal is to see if tebentafusp can shrink your tumor enough to help you keep your eye and your vision, or at least reduce how much treatment you'll need. Researchers will also watch closely for any side effects and check whether a blood test (looking for cancer DNA) can predict how well the drug is working for you. After your primary treatment, you'll have follow-up visits for up to 5 years to make sure you stay healthy.

NCT06414590
2 sites

A Personalized Immune Cell Treatment for Advanced Melanoma

H. Lee Moffitt Cancer Center and Research InstitutePHASE1 / PHASE2Recruiting

This trial tests a new way to fight advanced melanoma by using your own immune cells. Here's how it works: doctors remove a small piece of your tumor and grow your immune cells (called TILs) in the lab, then boost them with a special protein called CD40L to make them stronger at attacking cancer. After preparing your immune system with two chemotherapy drugs, they put these supercharged cells back into your body along with a medication called IL-2 that helps them work better. This treatment is designed for people with melanoma that has grown or spread despite other treatments. If you have uveal melanoma (eye cancer), you'd be in a smaller group of 10 patients getting this therapy. The trial has two phases: Phase I focuses on safety and finding the right dose, while Phase II looks at whether it actually works to shrink tumors. You should know this is experimental—it's not a standard treatment yet. You'll need surgery to remove tumor tissue, chemotherapy to prepare your body, and then the cell infusion. The goal is to teach your immune system to recognize and destroy cancer cells throughout your body using cells that already know how to fight your specific cancer.

NCT06961357
1 site

A Two-Step Treatment for Eye Cancer That Has Spread to the Liver

H. Lee Moffitt Cancer Center and Research InstitutePHASE2Recruiting

This trial tests a new approach to treating uveal melanoma (eye cancer) that has spread to your liver. The treatment has two parts, given one after the other. First, you'll receive melphalan—a strong cancer-fighting drug—delivered directly to your liver through a special catheter (a thin tube). This targets cancer cells in your liver while limiting damage to the rest of your body. Then, a few weeks later, you'll start tebentafusp, an immunotherapy drug given as an IV infusion. Tebentafusp works by training your immune system to recognize and attack melanoma cells. The idea behind combining these treatments is that the first drug (melphalan) damages cancer cells and releases substances that make them easier for your immune system to spot. Then tebentafusp comes in and helps your body's natural defenses finish the job. This trial is testing whether this one-two punch is more effective than either treatment alone. You'll need a specific genetic marker (HLA-A*02:01) for this trial—think of it like a cellular barcode that determines whether your immune system can respond to tebentafusp. Your doctor will test for this before you enroll. This is a Phase 2 trial, meaning researchers have already tested these drugs separately and now want to see if combining them works better and is safe.

NCT07276386
1 site

A Two-Drug Combination to Help Your Immune System Fight Metastatic Uveal Melanoma

H. Lee Moffitt Cancer Center and Research InstitutePHASE2Recruiting

This clinical trial is testing whether two drugs working together can help treat uveal melanoma that has spread to other parts of your body. You'll receive cemiplimab and ziv-aflibercept as an intravenous infusion (through an IV). The goal is to see if this combination can shrink your tumors or stop them from growing. Here's how the drugs work together: Cemiplimab acts like a 'brake release' for your immune system. Cancer cells have learned to hide from your immune cells by activating a 'stop' signal called PD-1. Cemiplimab blocks that stop signal, allowing your immune cells to recognize and attack the cancer. Meanwhile, ziv-aflibercept cuts off the blood supply that tumors need to grow. It does this by blocking a growth signal called VEGF. By combining these two approaches—boosting your immune system while starving the tumor—the researchers hope to give your body the best chance to fight back. This is a Phase II trial, which means the drugs have already been tested for basic safety in earlier studies. Now researchers want to see how well this combination actually works for uveal melanoma specifically. You'll have regular check-ups and imaging scans to monitor how your tumors respond.

NCT06121180
4 sites

A Two-Drug Combination to Stop Uveal Melanoma from Growing

H. Lee Moffitt Cancer Center and Research InstitutePHASE2Active

This trial tests whether two drugs working together can shrink or stop your uveal melanoma from spreading. You'll take one drug (binimetinib) as a pill twice a day, and receive the other drug (belinostat) as an IV infusion (through your vein) for 5 days every 3 weeks. The goal is to attack the cancer cells in two different ways at once—like using two different tools to fix a problem instead of just one. The study will last up to 16 cycles, which is about 4 months of treatment. During this time, doctors will watch closely to see if your tumors are shrinking and how you're handling the side effects. This is a Phase II trial, meaning the drugs have already been tested for safety in earlier studies, and now researchers want to see how well they actually work together against your specific type of cancer. If you join this trial, you'll have regular blood tests and scans to monitor your progress. Be honest with your doctors about any side effects you experience—that information helps them understand whether this combination is right for you and other patients.

NCT05170334
1 site

A New Treatment Using Your Own Immune Cells to Fight Melanoma That Has Spread or Stopped Responding to Other Treatments

H. Lee Moffitt Cancer Center and Research InstitutePHASE1Active

This trial is testing a completely new way to fight melanoma that has spread to other parts of your body or stopped responding to previous treatments. Here's how it works: Doctors will remove some of your tumor and extract special immune cells called T-cells that are already fighting your cancer. They'll grow millions of these cells in the lab, then put them back into your body. Before the cells go back in, you'll receive two chemotherapy drugs (cyclophosphamide and fludarabine) that temporarily weaken your immune system—this sounds counterintuitive, but it actually helps your new T-cells take over and do their job better. After the T-cells are infused, you'll receive IL-2, a protein that supercharges these cells to attack cancer more aggressively. This is a Phase 1 trial, which means it's the first time this specific treatment is being tested in humans. The main goal right now is to see if it's safe and if your body can tolerate it, not necessarily to prove it cures cancer. You'll be closely monitored throughout the process. This trial is open to people with uveal melanoma (eye cancer) as well as other types of melanoma that have spread or aren't responding to standard treatments. Before you can participate, you'll need to have your tumor tested to make sure you have enough of these special T-cells present—this is called a biomarker test. If you qualify, be prepared for an intensive treatment process that involves surgery to collect cells, time in the lab for cell growth, chemotherapy, and then the cell infusion with IL-2 support.

NCT05628883
1 site

SALOME: A Personalized Monitoring Plan to Catch Uveal Melanoma Spread Early

Institut CurieNARecruiting

This study is designed to help doctors catch uveal melanoma before it spreads to your liver—the most common place this cancer goes. Instead of using a one-size-fits-all approach, the SALOME study creates a personalized monitoring plan based on YOUR specific risk of the cancer coming back. If you're at high risk, you'll be followed more closely than patients at lower risk. Here's what being in the study means: You'll have liver MRI scans (detailed pictures of your liver) every 6 months to look for any early signs of spread. If your eye was removed (enucleation), you'll also give small blood samples every 6 months for at least 5 years. These blood samples aren't for treatment—they're for researchers to study special markers (like a cellular fingerprint) that might help predict who's most likely to have cancer return. This information could help doctors catch problems earlier and adjust your care plan as needed. The goal is simple: catch any spread as early as possible when treatment options are better, and give you peace of mind with a monitoring schedule tailored to your actual risk level.

NCT04424719
1 site

A Study About How Bel-sar Treatment Affects Your Daily Life

Aura BiosciencesN/ARecruiting

This study is asking you to share how you're doing while you're in another clinical trial called AU-011-301 (CoMpass) that's testing a new eye cancer treatment called bel-sar. You won't receive any new treatment in this study — instead, you'll answer questions about your life, symptoms, and how you're feeling over the next 2 years. The researchers want to understand the real-world impact of bel-sar beyond just medical measurements: Does it help you see better? Do you have fewer symptoms? Can you do the things you enjoy? Your honest answers help doctors understand whether this treatment actually improves patients' lives, not just what lab tests show. You'll complete surveys online at different time points — starting when you begin treatment and then regularly over 2 years (at weeks 4, 12, 20, 52, 65, 78, 91, and 104). The surveys include custom questions about your experience plus a standard eye cancer quality-of-life questionnaire. This is completely voluntary and separate from your main treatment trial, though you must be enrolled in the CoMpass trial to participate.

NCT07421739
1 site

Long-Term Check-In Study for Bel-sar Eye Cancer Treatment

Aura BiosciencesN/ANot Yet Recruiting

If you participated in the AU-011-301 trial for early eye melanoma (a type of cancer in the back of your eye), this follow-up study invites you to continue being monitored for about 5 more years. This is not a treatment study—you won't receive any new medication or procedures. Instead, doctors will simply check in with you regularly to see how you're doing and whether the bel-sar treatment (or the sham procedure you may have received) continues to work, what side effects show up over time, and how your overall health and quality of life are affected. The goal is to understand the long-term safety and effectiveness of bel-sar. Researchers want to know: Does the treatment keep working? Do any new side effects appear months or years later? Does the cancer stay controlled, or does it spread? How is your vision? This information will help doctors treat future patients with early eye melanoma better. You'll be asked to fill out questionnaires about how you're feeling and have regular eye exams and check-ups.

NCT07338968
0 sites

A New Immunotherapy Drug (Tebentafusp) for Uveal Melanoma That Hasn't Been Treated Before

Diwakar DavarPHASE2Recruiting

This clinical trial is testing a drug called tebentafusp for patients with uveal melanoma (eye cancer) that has spread to other parts of the body, particularly the liver. You're eligible for this trial if you have a specific genetic marker called HLA-A*0201 (think of it like a cellular barcode that determines whether your immune system can recognize cancer cells) and have never received treatment for your metastatic disease before. Tebentafusp works in a unique way: it's like a bridge that connects your own immune cells (called T cells) directly to cancer cells. The drug grabs onto a protein called gp100 that sits on melanoma cells, then uses your body's natural immune system to attack and kill those cancer cells. You'll receive the drug as an injection, starting with a lower dose that gradually increases over the first few weeks to help your body adjust. This is a Phase II trial, which means the drug has already shown promise in earlier studies, and now doctors are confirming it works well and monitoring side effects in a larger group of patients. The trial will track how well the drug shrinks your cancer and how you tolerate the treatment over time.

NCT06070012
3 sites

Combining Two Treatments to Fight Uveal Melanoma That Has Spread to the Liver

University of MiamiPHASE2Recruiting

This trial tests whether combining two different treatments works better than either one alone for uveal melanoma that has spread to your liver. You'll receive both tebentafusp (an immunotherapy drug given through an IV) and radioembolization (a procedure that delivers radiation directly to tumors in the liver). The radioembolization happens first, and then you'll start the tebentafusp within 28 days. The tebentafusp starts at a low dose and gradually increases over the first few weeks, then continues weekly as long as it's helping and you're tolerating it well. This is a Phase 2 trial, which means researchers have already tested these treatments separately and together in smaller groups, and now they want to see how well this combination works and what side effects patients experience. You'll be closely monitored throughout the study with blood tests and imaging scans. The goal is to slow or stop the cancer from growing while managing any side effects that come up.

NCT06627244
1 site

Checking Your Eye Health After Radiation Treatment for Eye Cancer

Medical University of ViennaN/ARecruiting

This study follows patients like you who have been treated with a special type of radiation therapy called stereotactic photon radiotherapy for uveal melanoma (eye cancer). The radiation is designed to kill cancer cells while sparing as much healthy eye tissue as possible. However, radiation can sometimes damage the blood vessels and nerves in the eye over time, which is why doctors want to carefully monitor your eye health. You'll come in for eye imaging appointments before your radiation treatment, and then again at 3, 6, 9, and 12 months after treatment. These appointments use several different types of eye imaging tools—think of them like taking different kinds of photographs and measurements of your eye to catch any changes early. The goal is to understand how often these side effects happen, how serious they are, and how to better protect patients' vision in the future.

NCT06280040
1 site

A Blood Test to Find Cancer Cells and Predict How Your Melanoma Will Respond to Treatment

IRCCS Azienda Ospedaliero-Universitaria di BolognaN/AActive

This study is looking for a better way to detect cancer cells that have escaped into your bloodstream and tiny molecules called microRNAs that might tell doctors how your uveal melanoma (or other types of melanoma that aren't on the skin) will behave. Instead of waiting weeks for imaging scans to show whether treatment is working, researchers want to develop a blood test that could give you answers much faster—like a 'report card' from your cancer cells themselves. You'll have blood samples taken at different points during your care, and researchers will analyze them to see if they can predict which treatments will work best for you and how your disease might progress. This is a research study, not a treatment—no one is giving you new drugs here. The goal is to create a tool that could help doctors make better decisions about your care in the future.

NCT06863870
1 site

Learning to Cope Better After Uveal Melanoma Diagnosis

Jonsson Comprehensive Cancer CenterNAActive

This study is about helping you feel less scared and worried after being diagnosed with uveal melanoma. Researchers know that eye cancer patients often feel uncertain about what comes next—whether your vision will stay the same, how treatment might affect you, and whether the cancer could spread. This trial tests whether watching educational videos can help you understand your diagnosis better and feel more in control. You'll be randomly placed into one of two groups. One group watches two 15-minute videos that explain uveal melanoma, what to expect during treatment and recovery, and how to manage the emotional side of having cancer. Both groups also get a sheet with mental health resources you can use. The study will check whether the videos help reduce feelings of depression and anxiety, and whether they help you feel less threatened by your diagnosis. This isn't about curing cancer—it's about helping you cope emotionally and mentally during your cancer journey.

NCT06075589
1 site

Testing a New Immune-Boosting Drug (IOA-244) for Advanced Cancers, Including Uveal Melanoma

iOncturaPHASE1Active

This is an early-stage study testing a brand-new drug called IOA-244 to see if it's safe and if it can help your immune system fight cancer more effectively. IOA-244 works by turning up the volume on a specific part of your immune system (called PI3K delta) that helps immune cells recognize and attack cancer cells. You would take it as a pill once a day. Depending on what type of cancer you have and how advanced it is, you might receive IOA-244 alone, or combined with other cancer drugs like avelumab (an immunotherapy given through an IV every 2 weeks). For uveal melanoma specifically, researchers want to see if IOA-244 combined with avelumab can help your body's immune system work harder against the cancer. This is a Phase 1 trial, which means it's the first time this drug is being tested in humans, so the main goal right now is to make sure it's safe and to figure out the right dose. You'll need to have regular check-ins with your medical team to monitor how you're responding and watch for any side effects. This trial is for adults with advanced or metastatic cancers (cancer that has spread), and uveal melanoma patients are specifically being studied.

NCT04328844
3 sites

A New Way to Fight Melanoma in the Liver: Training Your Own Immune Cells to Attack Cancer

Vastra Gotaland RegionPHASE1Not Yet Recruiting

This trial is testing a new treatment for melanoma that has spread to your liver. Here's how it works: Doctors will remove immune cells called T cells from your tumor, grow millions more of them in the lab, and then put them back into your body in a very targeted way. Before they do this, they'll use a special procedure to weaken the cancer cells in your liver with a chemotherapy drug called melphalan. Then they'll inject your trained immune cells directly into the blood vessels feeding your liver tumor, so they can attack the cancer where it lives. You'll also get small doses of a drug called interleukin-2 to help your immune cells work better. This is an early-stage trial (Phase 1), which means doctors are mainly checking if this treatment is safe and what side effects to expect. If you have melanoma that started in your eye (uveal melanoma) or on your skin and has spread to your liver, this trial might be for you.

NCT05903937
0 sites

Training Your Own Immune Cells to Fight Uveal Melanoma

Udai KammulaPHASE2Recruiting

This trial uses a powerful approach: doctors remove a piece of your cancer, find the immune cells already fighting it in that tumor, grow millions of copies of those cells in the lab, and then put them back into your body to attack the cancer throughout your body. Think of it like finding your body's best cancer-fighting soldiers and cloning an army of them. Here's what happens: First, you'll have surgery to remove a tumor spot (the doctors pick one that won't cause much harm). The lab grows your immune cells from that sample for several weeks. Then you get chemotherapy drugs (fludarabine and cyclophosphamide) to make room in your body for these new cells. Next, the lab infuses your grown immune cells back through an IV, followed by a drug called aldesleukin that supercharges these cells to attack cancer. You'll be monitored closely for 6 weeks to see if tumors shrink and to watch for side effects. This trial is for people with uveal melanoma that has spread to other parts of the body. About 20% of patients won't have enough cells grow in the lab, and they may have a second surgery to try again. This is a Phase 2 trial, meaning early results were promising and doctors want to confirm it works in more patients.

NCT03467516
1 site

Testing New Immune-Boosting Drugs Combined With Standard Cancer Treatments for Advanced Uveal Melanoma

M.D. Anderson Cancer CenterPHASE1Active

This study is testing whether three new experimental drugs (LVGN3616, LVGN6051, and sometimes LVGN7409) can help your body's immune system fight uveal melanoma better when combined with established cancer treatments. You would receive these new drugs along with one of two standard treatment combinations: either nab-paclitaxel (a chemotherapy drug) or bevacizumab plus cyclophosphamide (a different chemotherapy approach). All the experimental drugs are provided free by the company developing them. This is an early-stage study (Phase 1), which means doctors are still figuring out the right doses and watching carefully for side effects. The main goals are to find the safest and most effective dose, see how well the combination works against your cancer, and understand how long patients survive with this treatment. You'll also be asked about how you're feeling and functioning during treatment. Because this is a newer approach, there will be more frequent check-ins and blood tests than with standard treatment, but you'll be closely monitored at MD Anderson Cancer Center.

NCT05075993
1 site

Can a High-Fiber Diet Help Your Immunotherapy Work Better Against Melanoma?

M.D. Anderson Cancer CenterPHASE2Active

This study tests whether eating a diet higher in fiber (found in vegetables, fruits, and whole grains) can help your body's immune system fight melanoma more effectively while you're receiving immunotherapy. You'll be randomly assigned to eat either a high-fiber diet or a standard healthy diet for 11 weeks—both are nutritious whole foods recommended by the American Cancer Society, so either way you're eating well. The researchers want to understand how what you eat affects your gut bacteria (the trillions of tiny organisms in your digestive system), because emerging science suggests your gut health may influence how well your immune-boosting cancer treatment works. You'll provide food records so researchers can track what you're eating, and you'll answer questionnaires about any digestive side effects and how you're feeling overall. The study will also monitor whether the high-fiber diet causes any problems or makes your immunotherapy side effects worse. This is important because we need to know not just whether fiber helps, but whether it's safe and tolerable for people undergoing cancer treatment. After the 11-week diet period, you'll have a follow-up visit at 12 weeks to see how you're doing.

NCT04645680
1 site

Testing a New Drug (Darovasertib) Before and After Eye Cancer Surgery

St Vincent's Hospital, SydneyPHASE2Active

This study is testing whether a new drug called darovasertib is safe and tolerable for people with high-risk uveal melanoma (eye cancer) who are planning to have their eye removed. You would take darovasertib by mouth (300mg tablets twice a day) for up to 4 weeks before your surgery, and then continue taking it for up to 6 months after surgery if it's working well and you're tolerating it okay. The goal is to see if this drug can help fight the cancer and prevent it from coming back. Researchers want to understand how darovasertib works in your body and how your body processes it. They're also watching carefully to make sure the drug is safe and that side effects are manageable. This is an early-stage study (Phase 2), which means the drug has shown some promise in the lab and in very small groups, but doctors are still learning the best way to use it for eye cancer patients like you. If you join this trial, you'll have close medical supervision, regular check-ins, and blood tests to monitor how you're doing. This is a chance to access a potentially helpful new treatment while contributing to research that could help future patients with uveal melanoma.

NCT05187884
2 sites

Testing Two Drugs Together to Help Your Immune System Fight Uveal Melanoma

St Vincent's Hospital, SydneyPHASE1Recruiting

This trial tests whether combining two drugs—tebentafusp and roginolisib—works better than tebentafusp alone for uveal melanoma that has spread to other parts of your body. You'll start with tebentafusp first, then add roginolisib starting in cycle 4. The goal is to help your immune system's T-cells (special infection-fighting cells) stay strong and keep fighting the cancer longer. This is an early-stage study (Phase 1), which means researchers are still figuring out the best dose and watching carefully for side effects. You'll need a biomarker test to see if you're eligible—specifically, they're checking for HLA-A*02:01, which is like a cellular barcode that determines whether your immune system can respond to tebentafusp.

NCT07203391
2 sites

A New Cell-Based Treatment vs. Traditional Chemotherapy for Advanced Melanoma

Qingdao Sino-Cell Biomedicine Co., Ltd.PHASE2Not Yet Recruiting

This trial is testing a new treatment called HS-IT101 that uses your own immune cells to fight advanced melanoma (skin cancer). Here's how it works: doctors will remove a small piece of your tumor, then grow special immune cells called TILs (tumor-infiltrating lymphocytes) from that tissue in the lab. These are cells your body already sent to fight the cancer. After growing millions of these cells, they'll give you medications to temporarily weaken your immune system, then infuse the grown cells back into your bloodstream along with a hormone called IL-2 that helps these cells work better. You'll receive this treatment just once. You'll be randomly assigned to either get this new cell treatment or standard chemotherapy (the current go-to treatment for advanced melanoma). The trial will follow 90 patients total to see which approach works better and is safer. This is important research because your melanoma is advanced, meaning it has spread, and doctors are looking for better options than chemotherapy alone.

NCT07406724
0 sites